Monoclonal Antibody Development Targeting IL-6 for Autoimmune Diseases

Creative Biolabs provides state-of-art services for any monoclonal antibody development project with qualitative measurements. Our multidisciplinary team will provide flexible solutions for interleukin (IL)-6 antibody construction, safety, and toxicity evaluation. We are also specialized in improving candidate IL-6 antibodies for the treatment of autoimmune diseases, which can boost long-term efficacy and reduce the cost to a more affordable level.

Introduction to IL-6 in Autoimmune Diseases

IL-6 is a key cytokine that plays an important role in mediating immune responses and acute inflammatory reactions. IL-6 can be produced by a wide variety of cells, including B cells, T cells, smooth muscle cells, stromal cells, and macrophages. Moreover, IL-6 can be used as a growth factor for different tumors, such as renal cell carcinomas and sarcoma.

Meanwhile, many studies have indicated that the dysfunction of IL-6 production is associated with the pathology of various disease types, especially for autoimmune diseases. For example, high levels of IL-6 have been identified in a range of autoimmune diseases, such as rheumatoid arthritis (RA), antigen-induced arthritis (AIA), psoriasis, as well as allergic encephalomyelitis. As a result, arrays of therapeutic strategies targeting the IL-6 pathway have been developed for the treatment of autoimmune diseases. Several monoclonal antibodies against IL-6 or its receptors have been broadly used both in pre-clinical and clinical trials.

Fig.1 The pathological contribution of IL-6 to rheumatoid arthritis.1

Monoclonal Antibody Development Service Targeting IL-6

IL-6, a potent pro-inflammatory cytokine, is critical for regulating immune responses and triggering host defense against pathogens. Currently, Creative Biolabs has built up a wide spectrum of monoclonal antibody discovery services targeting IL-6 or its receptors to suit any requirement of our clients in the treatment of various autoimmune diseases. Up to now, we can offer a full range of IL-6-based monoclonal antibody development services based on the specific autoimmune disease types, including but not limited to, juvenile idiopathic arthritis (JIA), psoriasis, RA, and autoimmune oophoritis. The data derived from our labs have revealed that these anti-IL-6 or anti-IL-6 receptor monoclonal antibodies can significantly improve clinical outcomes of patients with polyarthritis.

Besides, we have also established a panel of assays and have been equipped with many optimization technologies to enhance the performance of candidate IL-6 or IL-6 receptor antibodies of your interest. In a recent study, five novel humanized anti-IL-6 monoclonal antibodies have been characterized by using epitope mapping. Also, these antibodies have been analyzed for applications in different immunological assays, such as enzyme-linked immune sorbent assay (ELISA), fluorescence-activated cell sorter (FACS), and western blot (WB). These findings support the use of IL-6 or IL-6 receptor antibodies as promising diagnostic or therapeutic tools for treating various autoimmune diseases.

Creative Biolabs is a leader in the field of autoimmune disease-mediated monoclonal antibody development for years. With in-depth expertise in IL-6 biological activity analysis, antibody safety studies, as well as anti-IL-6 antibody therapy evaluation. In our company, our scientists specialized in IL-6 studies will work with you to develop the most appropriate monoclonal antibody discovery strategy that will offer reproducible data for your research. If you are interested in our services, please contact us for more details.

Reference

1. Ogata, Atsushi, and Toshio Tanaka. "Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions." International journal of rheumatology 2012.1 (2012): 946048. Distributed under Open Access license CC BY 4.0, without modification.

For Research Use Only | Not For Clinical Use